Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2020-01-13 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA
Regulatory Filings
2020-01-13 English
Lynparza granted FDA Priority Review for PAOLA-1
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the London Stock Exchange's RNS service. The content details a regulatory update: the FDA granted Priority Review for a supplemental New Drug Application (sNDA) for Lynparza, based on Phase III trial data (PAOLA-1). This is a specific corporate event announcement concerning regulatory progress, not a comprehensive financial report (like 10-K or IR) or a general earnings release (ER). Since it is a formal regulatory announcement distributed through the RNS system that doesn't fit perfectly into other specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS, which serves as a primary information provider announcement.
2020-01-13 English
Update on Epanova Phase III STRENGTH trial
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content details a clinical trial update (Phase III STRENGTH trial for Epanova) where the trial was recommended for discontinuation due to low likelihood of benefit. It also discusses financial considerations related to asset impairment and inventory write-down, which are material events. Since this is a specific, material announcement released through the RNS system that does not fit neatly into categories like Earnings Release (ER), Interim Report (IR), or Director's Dealing (DIRS), the most appropriate classification is the general regulatory announcement category, RNS.
2020-01-13 English
LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA
Regulatory Filings
2020-01-06 English
FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED
Regulatory Filings
2020-01-06 English
Farxiga granted FDA heart failure Priority Review
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content describes a specific corporate event: the FDA granting Priority Review for a drug (Farxiga). This is a material announcement concerning regulatory progress and product development, not a full financial report (like 10-K or IR), a transcript (CT), or a formal presentation (IP). Since it is a general regulatory announcement that doesn't fit the highly specific categories like DIV, DIRS, or MANG, the most appropriate classification is the general regulatory filing category, RNS.
2020-01-06 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.